Xiaoyu Wen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoyu Wen has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Hui Wang
Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University
4 shared publicationsDiandian Hao
Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University
3 shared publicationsJialin Du
Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University
3 shared publications- Ruihua Zhang
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing Ditan Hospital Capital Medical University Beijing China
2 shared publications Yu Zhang
Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University
2 shared publicationsYu-Lin Ren
Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University
2 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1882357
Hepatic expression of IL-8, IL-10, and CXCL-14 in drug-induced liver injury: correlation with histopathology and prognostic value
Background: Drug-induced liver injury (DILI) lacks reliable tissue-based biomarkers for diagnosing disease severity and predicting outcomes. This study investigated the hepatic expression of interleukin-8 (IL-8), interleukin-10 (IL-10), and chemokine ligand-14 (CXCL-14) in DILI and evaluated their diagnostic and prognostic relevance. Methods: Forty biopsy-proven DILI patients and ten healthy controls were enrolled. Immunohistochemistry was performed to quantify hepatic IL-8, IL-10, and CXCL-14 expression. Clinical variables, inflammation grades, and fibrosis stages were analyzed. Correlation analysis, logistic regression, and ROC curves were applied to assess diagnostic value and prognosis. Results: Hepatic IL-8, IL-10, and CXCL-14 were significantly elevated in DILI patients compared with controls ( P < 0.05). IL-8 and CXCL-14 levels varied with inflammation grade, and IL-8 also correlated with fibrosis. Spearman analysis showed positive correlations of IL-8, IL-10, and CXCL-14 with inflammation severity, while IL-8 and CXCL-14 were associated with fibrosis. CXCL-14 additionally correlated with AST and GGT. Multivariate analysis identified CXCL-14 as an independent predictor of unfavorable outcomes (OR = 1.769, 95% CI: 1.062–2.947, P = 0.029). ROC analysis demonstrated good prognostic performance (AUC = 0.848). Conclusion: IL-8, IL-10, and CXCL-14 were significantly upregulated in DILI liver tissue. The expression level of IL-8 was closely associated with hepatic inflammation and fibrosis and may serve as a potential indicator of disease severity. CXCL-14 was identified as an independent factor associated with clinical prognosis and demonstrated promising prognostic performance in this cohort. These findings suggest that tissue chemokine profiling may have potential value for risk stratification in DILI, although further validation in larger prospective studies is warranted.
- 12 August 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1882357
Open AccessHepatic expression of IL-8, IL-10, and CXCL-14 in drug-induced liver injury: correlation with histopathology and prognostic value
Background: Drug-induced liver injury (DILI) lacks reliable tissue-based biomarkers for diagnosing disease severity and predicting outcomes. This study investigated the hepatic expression of interleukin-8 (IL-8), interleukin-10 (IL-10), and chemokine ligand-14 (CXCL-14) in DILI and evaluated their diagnostic and prognostic relevance. Methods: Forty biopsy-proven DILI patients and ten healthy controls were enrolled. Immunohistochemistry was performed to quantify hepatic IL-8, IL-10, and CXCL-14 expression. Clinical variables, inflammation grades, and fibrosis stages were analyzed. Correlation analysis, logistic regression, and ROC curves were applied to assess diagnostic value and prognosis. Results: Hepatic IL-8, IL-10, and CXCL-14 were significantly elevated in DILI patients compared with controls ( P < 0.05). IL-8 and CXCL-14 levels varied with inflammation grade, and IL-8 also correlated with fibrosis. Spearman analysis showed positive correlations of IL-8, IL-10, and CXCL-14 with inflammation severity, while IL-8 and CXCL-14 were associated with fibrosis. CXCL-14 additionally correlated with AST and GGT. Multivariate analysis identified CXCL-14 as an independent predictor of unfavorable outcomes (OR = 1.769, 95% CI: 1.062–2.947, P = 0.029). ROC analysis demonstrated good prognostic performance (AUC = 0.848). Conclusion: IL-8, IL-10, and CXCL-14 were significantly upregulated in DILI liver tissue. The expression level of IL-8 was closely associated with hepatic inflammation and fibrosis and may serve as a potential indicator of disease severity. CXCL-14 was identified as an independent factor associated with clinical prognosis and demonstrated promising prognostic performance in this cohort. These findings suggest that tissue chemokine profiling may have potential value for risk stratification in DILI, although further validation in larger prospective studies is warranted.
- Open Access
- 29 January 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1710414
The incidence of chronic drug-induced liver injury: a systematic review and meta-analysis
Objectives: Drug-induced liver injury (DILI) is a recognized adverse drug event. Although most cases present with acute hepatic damage, evidence indicates that a proportion progress to persistent liver injury. The absence of a standardized definition for chronic DILI has contributed to significant discrepancies in reported incidence rates across clinical studies. This meta-analysis aims to determine the pooled incidence of chronic DILI, providing robust epidemiological evidence. Methods: This meta-analysis was conducted in accordance with the PRISMA and MOOSE guidelines. A systematic search was conducted in PubMed, Web of Science, Embase and Cochrane Library databases from their respective inception dates to 11 July 2025. The quality of cohort studies was assessed using the NOS. A random-effects model was used to calculate the pooled incidence of chronic DILI, expressed as corresponding 95% confidence intervals ( CI s). Subgroup analyses were performed to explore potential sources of heterogeneity. Publication bias was assessed and sensitivity analyses were conducted. All statistical tests were two-tailed, and a P value CI : 10.35%–18.29%; I 2 = 80.76%). Four studies that reported the incidence of chronic DILI based on a 12-month follow-up (without distinguishing causative drugs) showed a pooled incidence of 7.95% (95% CI : 5.16%–11.24%; I 2 = 54.8%). The pooled incidence of chronic DILI attributed to antimicrobial drugs (6-month follow-up) was 14.56% (95% CI : 10.86%–18.65%; I 2 = 0%). Conclusion: Chronic DILI accounts for a clinically certain proportion of DILI cases. Greater emphasis should be placed on the long-term management and follow-up of patients with DILI to mitigate the risk of chronic progression. Systematic Review Registration: https://inplasy.com , identifier INPLASY202580021.
- 29 January 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1710414
Open AccessThe incidence of chronic drug-induced liver injury: a systematic review and meta-analysis
Objectives: Drug-induced liver injury (DILI) is a recognized adverse drug event. Although most cases present with acute hepatic damage, evidence indicates that a proportion progress to persistent liver injury. The absence of a standardized definition for chronic DILI has contributed to significant discrepancies in reported incidence rates across clinical studies. This meta-analysis aims to determine the pooled incidence of chronic DILI, providing robust epidemiological evidence. Methods: This meta-analysis was conducted in accordance with the PRISMA and MOOSE guidelines. A systematic search was conducted in PubMed, Web of Science, Embase and Cochrane Library databases from their respective inception dates to 11 July 2025. The quality of cohort studies was assessed using the NOS. A random-effects model was used to calculate the pooled incidence of chronic DILI, expressed as corresponding 95% confidence intervals ( CI s). Subgroup analyses were performed to explore potential sources of heterogeneity. Publication bias was assessed and sensitivity analyses were conducted. All statistical tests were two-tailed, and a P value CI : 10.35%–18.29%; I 2 = 80.76%). Four studies that reported the incidence of chronic DILI based on a 12-month follow-up (without distinguishing causative drugs) showed a pooled incidence of 7.95% (95% CI : 5.16%–11.24%; I 2 = 54.8%). The pooled incidence of chronic DILI attributed to antimicrobial drugs (6-month follow-up) was 14.56% (95% CI : 10.86%–18.65%; I 2 = 0%). Conclusion: Chronic DILI accounts for a clinically certain proportion of DILI cases. Greater emphasis should be placed on the long-term management and follow-up of patients with DILI to mitigate the risk of chronic progression. Systematic Review Registration: https://inplasy.com , identifier INPLASY202580021.
- Open Access
- 28 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1572054
Development and validation of a prediction model for invasive syndrome in liver abscess patients based on LASSO regression: a multi-center retrospective cohort study in China
Background: Patients with liver abscess are at high risk of developing invasive K. pneumonia liver abscess syndrome (IKPLAS), which can worsen survival and quality of life. Early identification of high-risk patients is crucial. This study aimed to identify risk factors for IKPLAS and develop a predictive model to guide early intervention. Methods: We retrospectively collected data from 1,762 liver abscess patients at the First Hospital of Jilin University between 2015 and 2024. Patients were randomly divided into a training set and an internal validation set at a 7:3 ratio, and 203 patients from another hospital served as an external validation cohort. The SMOTE algorithm was applied to address data imbalance. Independent risk factors were identified using LASSO and logistic regression analyses, and the performance of different models was compared. Ultimately, a LASSO-based logistic regression model was used to construct a predictive nomogram. Model performance was comprehensively evaluated using the area under the receiver operating characteristic curve (AUC), decision curve analysis (DCA), clinical impact curve (CIC), and calibration curve. An online risk calculator was also developed for clinical use. Results: Among 1,965 patients (1,304 males, 661 females; mean age 58.96 ± 13.07 years), 548 (28.9%) developed IKPLAS. Independent risk factors included CRP (OR = 1.005, 95% CI: 1.003–1.007), PLT (OR = 0.995, 95% CI: 0.994–0.997), Prior biliary disease (OR = 1.137, 95% CI: 1.025–2.571), Fever (OR = 2.196, 95% CI: 1.292–3.824), Pleural effusion (OR = 7.355, 95% CI: 4.883–14.761), Ascites (OR = 8.786, 95% CI: 5.141–9.342), Broth culture (OR = 2.264, 95% CI: 1.186–3.371), DM (OR = 2.516, 95% CI: 1.757–3.63), and TBIL (OR = 1.006, 95% CI: 1.002–1.010). The nomogram achieved AUCs of 0.960, 0.920, and 0.892 in the training, internal, and external validation sets, respectively, with good calibration and clinical utility. Conclusion: We developed a nine-factor nomogram to predict individualized IKPLAS risk, demonstrating high discrimination and calibration, supporting early identification of high-risk patients and personalized management.
- 28 November 2025
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 12, 1572054
Open AccessDevelopment and validation of a prediction model for invasive syndrome in liver abscess patients based on LASSO regression: a multi-center retrospective cohort study in China
Background: Patients with liver abscess are at high risk of developing invasive K. pneumonia liver abscess syndrome (IKPLAS), which can worsen survival and quality of life. Early identification of high-risk patients is crucial. This study aimed to identify risk factors for IKPLAS and develop a predictive model to guide early intervention. Methods: We retrospectively collected data from 1,762 liver abscess patients at the First Hospital of Jilin University between 2015 and 2024. Patients were randomly divided into a training set and an internal validation set at a 7:3 ratio, and 203 patients from another hospital served as an external validation cohort. The SMOTE algorithm was applied to address data imbalance. Independent risk factors were identified using LASSO and logistic regression analyses, and the performance of different models was compared. Ultimately, a LASSO-based logistic regression model was used to construct a predictive nomogram. Model performance was comprehensively evaluated using the area under the receiver operating characteristic curve (AUC), decision curve analysis (DCA), clinical impact curve (CIC), and calibration curve. An online risk calculator was also developed for clinical use. Results: Among 1,965 patients (1,304 males, 661 females; mean age 58.96 ± 13.07 years), 548 (28.9%) developed IKPLAS. Independent risk factors included CRP (OR = 1.005, 95% CI: 1.003–1.007), PLT (OR = 0.995, 95% CI: 0.994–0.997), Prior biliary disease (OR = 1.137, 95% CI: 1.025–2.571), Fever (OR = 2.196, 95% CI: 1.292–3.824), Pleural effusion (OR = 7.355, 95% CI: 4.883–14.761), Ascites (OR = 8.786, 95% CI: 5.141–9.342), Broth culture (OR = 2.264, 95% CI: 1.186–3.371), DM (OR = 2.516, 95% CI: 1.757–3.63), and TBIL (OR = 1.006, 95% CI: 1.002–1.010). The nomogram achieved AUCs of 0.960, 0.920, and 0.892 in the training, internal, and external validation sets, respectively, with good calibration and clinical utility. Conclusion: We developed a nine-factor nomogram to predict individualized IKPLAS risk, demonstrating high discrimination and calibration, supporting early identification of high-risk patients and personalized management.
- Open Access
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Serum proteomics identify biomarkers and pathogenesis of portopulmonary hypertension diagnosed based on echocardiography
Portal pulmonary hypertension (PoPH), a severe complication of portal hypertension (PHTN), is marked by elevated pulmonary arterial pressure, but its pathophysiological mechanisms are unclear. This study used proteomics to identify differentially expressed proteins (DEPs) and genes in Patients with PoPH compared to those with PHTN and healthy controls (HC), aiming to uncover potential biomarkers for diagnosis and treatment. Patients with liver cirrhosis and PHTN, admitted between January 2023 and May 2024, were classified into PoPH and non-PoPH (PHTN) groups based on echocardiography. Serum from 12 PoPH, 12 PHTN, and 6 HC was analyzed using data-independent acquisition (DIA) proteomics to identify DEPs. Protein-protein interaction (PPI) networks identified key DEPs, and ELISA was performed for biomarker validation. Compared to HC, 374 proteins were upregulated and 115 downregulated in PoPH, while 18 were upregulated and 38 downregulated in PHTN. KEGG and GO analyses linked DEPs to immune response, metabolism, and cell signaling. Thirty-five proteins distinguish PoPH from HC and PHTN. Vitronectin (VTN, P04004) was correlated with RDW (R = -0.56, P < 0.01) and PLT (R = 0.52, P < 0.01). ELISA confirmed lower VTN levels in PoPH (P < 0.05). This study identified 35 serum proteins involved in PoPH, with VTN as a potential biomarker for distinguishing PoPH from PHTN and HC. Further research is needed to explore these findings.
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-12
Open AccessSerum proteomics identify biomarkers and pathogenesis of portopulmonary hypertension diagnosed based on echocardiography
Portal pulmonary hypertension (PoPH), a severe complication of portal hypertension (PHTN), is marked by elevated pulmonary arterial pressure, but its pathophysiological mechanisms are unclear. This study used proteomics to identify differentially expressed proteins (DEPs) and genes in Patients with PoPH compared to those with PHTN and healthy controls (HC), aiming to uncover potential biomarkers for diagnosis and treatment. Patients with liver cirrhosis and PHTN, admitted between January 2023 and May 2024, were classified into PoPH and non-PoPH (PHTN) groups based on echocardiography. Serum from 12 PoPH, 12 PHTN, and 6 HC was analyzed using data-independent acquisition (DIA) proteomics to identify DEPs. Protein-protein interaction (PPI) networks identified key DEPs, and ELISA was performed for biomarker validation. Compared to HC, 374 proteins were upregulated and 115 downregulated in PoPH, while 18 were upregulated and 38 downregulated in PHTN. KEGG and GO analyses linked DEPs to immune response, metabolism, and cell signaling. Thirty-five proteins distinguish PoPH from HC and PHTN. Vitronectin (VTN, P04004) was correlated with RDW (R = -0.56, P < 0.01) and PLT (R = 0.52, P < 0.01). ELISA confirmed lower VTN levels in PoPH (P < 0.05). This study identified 35 serum proteins involved in PoPH, with VTN as a potential biomarker for distinguishing PoPH from PHTN and HC. Further research is needed to explore these findings.
- Open Access
- 9 December 2024
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 37 (4) , 483-487
Summary of clinical features of 1800 cases of pyogenic liver abscess
Objective: This study aimed to summarize the clinical and microbiological characteristics of patients with pyogenic liver abscess (PLA) and to explore the clinical features of PLA with extrahepatic migratory infection (EMI). Methods: A retrospective analysis was conducted on clinical data from 1800 PLA patients at Jilin University First Hospital from January 2019 to December 2023. Patients were divided into two groups based on the presence of EMI: with EMI and without EMI. Clinical features and prognoses of the two groups were compared using rank-sum tests and chi-square tests for continuous and categorical data, respectively. Results: PLA patients were predominantly male (65.56%) with an average age of 60. Abscesses were mainly located in the right lobe (64.83%) and were often single (68.17%). Klebsiella pneumoniae was the primary pathogen (68.46%), with 9.50% of strains being multidrug-resistant. The majority of patients improved with effective treatment (96.17%). Compared with the non-EMI group, patients with EMI were younger, had longer hospital stays, smaller abscesses, and a higher incidence of diabetes and cerebrovascular disease, with poorer prognoses. Conclusion: PLA is most commonly observed in middle-aged and elderly males, often presenting as single abscesses in the right lobe, with diabetes as a frequent underlying condition. Most patients recover with appropriate antibiotic treatment and ultrasound-guided drainage. PLA patients with EMI generally have poorer outcomes and require special attention.
- 9 December 2024
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 37 (4) , 483-487
Open AccessSummary of clinical features of 1800 cases of pyogenic liver abscess
Objective: This study aimed to summarize the clinical and microbiological characteristics of patients with pyogenic liver abscess (PLA) and to explore the clinical features of PLA with extrahepatic migratory infection (EMI). Methods: A retrospective analysis was conducted on clinical data from 1800 PLA patients at Jilin University First Hospital from January 2019 to December 2023. Patients were divided into two groups based on the presence of EMI: with EMI and without EMI. Clinical features and prognoses of the two groups were compared using rank-sum tests and chi-square tests for continuous and categorical data, respectively. Results: PLA patients were predominantly male (65.56%) with an average age of 60. Abscesses were mainly located in the right lobe (64.83%) and were often single (68.17%). Klebsiella pneumoniae was the primary pathogen (68.46%), with 9.50% of strains being multidrug-resistant. The majority of patients improved with effective treatment (96.17%). Compared with the non-EMI group, patients with EMI were younger, had longer hospital stays, smaller abscesses, and a higher incidence of diabetes and cerebrovascular disease, with poorer prognoses. Conclusion: PLA is most commonly observed in middle-aged and elderly males, often presenting as single abscesses in the right lobe, with diabetes as a frequent underlying condition. Most patients recover with appropriate antibiotic treatment and ultrasound-guided drainage. PLA patients with EMI generally have poorer outcomes and require special attention.
- Open Access
- 12 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-15
ELISA genotyping of hepatitis B virus in China with antibodies specific for genotypes B and C
Hepatitis B virus (HBV) causes hepatitis B (HB) and distinct HBV genotypes can lead to different prognoses. However, HBV genotyping is rarely done in clinics, because the traditional method by PCR-based DNA sequencing is impractical for clinical diagnosis with tedious process and low success rate. Herein, we have established an ELISA-based genotyping method to quickly determine the HBV genotypes of HB patients in China. First, two commercial antibodies, 16D12 and 6H3 specific for HBV genotypes B and C respectively, are chosen as capture antibodies, since these two genotypes dominate in China. Then two home-made genotype-specific antibodies, B19 and C04, are used as the detection antibodies for genotypes B and C in sandwiched ELISA. The ELISA kit shows high sensitivity (> 95%) and specificity (> 95%) in detecting genotypes B and C of Chinese HB patients. Moreover, the ELISA kit has demonstrated higher success rate (98.7%) than PCR-based DNA sequencing (93.5%) and a commercial PCR-based genotyping kit (92.2%) for sera with HBV DNA ≥ 1000 IU/mL and HBsAg ≥ 250 IU/mL. Such an advantage is more obvious for the sera with HBV DNA < 1000 IU/mL. The kappa analysis between the ELISA and PCR-based DNA sequencing results exhibits a kappa of 0.836, indicating a good correlation.
- 12 October 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-15
Open AccessELISA genotyping of hepatitis B virus in China with antibodies specific for genotypes B and C
Hepatitis B virus (HBV) causes hepatitis B (HB) and distinct HBV genotypes can lead to different prognoses. However, HBV genotyping is rarely done in clinics, because the traditional method by PCR-based DNA sequencing is impractical for clinical diagnosis with tedious process and low success rate. Herein, we have established an ELISA-based genotyping method to quickly determine the HBV genotypes of HB patients in China. First, two commercial antibodies, 16D12 and 6H3 specific for HBV genotypes B and C respectively, are chosen as capture antibodies, since these two genotypes dominate in China. Then two home-made genotype-specific antibodies, B19 and C04, are used as the detection antibodies for genotypes B and C in sandwiched ELISA. The ELISA kit shows high sensitivity (> 95%) and specificity (> 95%) in detecting genotypes B and C of Chinese HB patients. Moreover, the ELISA kit has demonstrated higher success rate (98.7%) than PCR-based DNA sequencing (93.5%) and a commercial PCR-based genotyping kit (92.2%) for sera with HBV DNA ≥ 1000 IU/mL and HBsAg ≥ 250 IU/mL. Such an advantage is more obvious for the sera with HBV DNA < 1000 IU/mL. The kappa analysis between the ELISA and PCR-based DNA sequencing results exhibits a kappa of 0.836, indicating a good correlation.
- Open Access
- 8 December 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1070802
Correlation between serum cytokines and clinicopathological features in patients with drug-induced liver injury
Objectives: Changes in serum levels of cytokines have been proposed as possible biological markers of tissue damage, including drug-induced liver injury (DILI). Here, we aimed to screen cytokine markers that have guiding significance for the degree of inflammation of DILI.Patients and methods: 54 patients with DILI were retrospectively analyzed as the experimental group, and 14 healthy subjects were randomly selected as the control group. A total of 20 cytokines were detected by using a cytokine protein antibody chip, and differentially expressed proteins were screened.Results: There were significant differences in serum cytokines between DILI patients and healthy controls. Compared with the control group, the DILI group expressed 11 differential proteins. IL-8, TNF RII, TNFα, TNF RI, MIP-1β, MIP-1α, and IL-1β were differentially expressed in DILI patients with different degrees of inflammation from G1 to G4. MIG, IL-12p40, and IL-10 were differentially expressed in the higher degree of inflammation groups (G2, G3, and G4 groups). Tissue inhibitor of metalloproteinases-1 (TIMP-1) was differentially expressed in the group with the highest inflammation degree (G4 group). Chemokine C-C motif ligand 1 (I-309) was only differentially expressed in the lowest inflammation group (G1 group).Conclusion: The changes and differential expression of specific cytokine levels were helpful for evaluating different degrees of inflammation of DILI.
- 8 December 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1070802
Open AccessCorrelation between serum cytokines and clinicopathological features in patients with drug-induced liver injury
Objectives: Changes in serum levels of cytokines have been proposed as possible biological markers of tissue damage, including drug-induced liver injury (DILI). Here, we aimed to screen cytokine markers that have guiding significance for the degree of inflammation of DILI.Patients and methods: 54 patients with DILI were retrospectively analyzed as the experimental group, and 14 healthy subjects were randomly selected as the control group. A total of 20 cytokines were detected by using a cytokine protein antibody chip, and differentially expressed proteins were screened.Results: There were significant differences in serum cytokines between DILI patients and healthy controls. Compared with the control group, the DILI group expressed 11 differential proteins. IL-8, TNF RII, TNFα, TNF RI, MIP-1β, MIP-1α, and IL-1β were differentially expressed in DILI patients with different degrees of inflammation from G1 to G4. MIG, IL-12p40, and IL-10 were differentially expressed in the higher degree of inflammation groups (G2, G3, and G4 groups). Tissue inhibitor of metalloproteinases-1 (TIMP-1) was differentially expressed in the group with the highest inflammation degree (G4 group). Chemokine C-C motif ligand 1 (I-309) was only differentially expressed in the lowest inflammation group (G1 group).Conclusion: The changes and differential expression of specific cytokine levels were helpful for evaluating different degrees of inflammation of DILI.
- Open Access
- 16 November 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 991568
Efficacy evaluation of pulmonary hypertension therapy in patients with portal pulmonary hypertension: A systematic review and meta-analysis
Objective: To determine the therapeutic effect of pulmonary arterial hypertension (PAH) agents for portal pulmonary hypertension (POPH).Design: Systematic review and meta-analysis.Background: POPH is a serious complication of end-stage liver disease with a low survival rate. Liver transplantation (LT) is an effective treatment. Due to the presence of POPH, some patients cannot undergo LT. After PAH treatment, patients with POPH can obtain good hemodynamics and cardiac function for LT, but there are no standard guidelines.Methods: Two independent researchers searched PubMed, EMBASE, Cochrane Library, and Web of Science for studies published from inception to 27 September 2022, focusing on the changes in hemodynamics and cardiac function in all patients with POPH to understand the effect of PAH treatment on the entire population of POPH patients. Among these, we specifically analyzed the changes in hemodynamics and cardiac function in moderate and severe POPH patients. After collecting the relevant data, a meta-analysis was carried out using the R program meta-package.Results: A total of 2,775 literatures were retrieved, and 24 literatures were included. The results showed that in all POPH patients (n = 1,046), the following indicators were significantly improved with PAH agents: mPAP: (MD = −9.11 mmHg, p < 0.0001); PVR: (MD = −239.33 dyn·s·cm−5, p < 0.0001); CO: (MD = 1.71 L/min, p < 0.0001); cardiac index: (MD = 0.87 L/(min·m2), p < 0.0001); 6MWD: (MD = 43.41 m, p < 0.0001). In patients with moderate to severe POPH (n = 235), the following indicators improved significantly with PAH agents: mPAP (MD = −9.63 mmHg, p < 0.0001); PVR (MD = −259.78 dyn·s·cm−5, p < 0.0001); CO (MD = 1.76 L/min, p < 0.0001); Cardiac index: (MD = 1.01 L/(min·m2), p = 0.0027); 6MWD: (MD = 61.30 m, p < 0.0001).Conclusion: The application of PAH agents can improve cardiopulmonary hemodynamics and cardiac function in patients with POPH, especially in patients with moderate to severe POPH, and the above changes are more positive.Systematic Review Registration:https://inplasy.com, identifier INPLASY202250034.
- 16 November 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 991568
Open AccessEfficacy evaluation of pulmonary hypertension therapy in patients with portal pulmonary hypertension: A systematic review and meta-analysis
Objective: To determine the therapeutic effect of pulmonary arterial hypertension (PAH) agents for portal pulmonary hypertension (POPH).Design: Systematic review and meta-analysis.Background: POPH is a serious complication of end-stage liver disease with a low survival rate. Liver transplantation (LT) is an effective treatment. Due to the presence of POPH, some patients cannot undergo LT. After PAH treatment, patients with POPH can obtain good hemodynamics and cardiac function for LT, but there are no standard guidelines.Methods: Two independent researchers searched PubMed, EMBASE, Cochrane Library, and Web of Science for studies published from inception to 27 September 2022, focusing on the changes in hemodynamics and cardiac function in all patients with POPH to understand the effect of PAH treatment on the entire population of POPH patients. Among these, we specifically analyzed the changes in hemodynamics and cardiac function in moderate and severe POPH patients. After collecting the relevant data, a meta-analysis was carried out using the R program meta-package.Results: A total of 2,775 literatures were retrieved, and 24 literatures were included. The results showed that in all POPH patients (n = 1,046), the following indicators were significantly improved with PAH agents: mPAP: (MD = −9.11 mmHg, p < 0.0001); PVR: (MD = −239.33 dyn·s·cm−5, p < 0.0001); CO: (MD = 1.71 L/min, p < 0.0001); cardiac index: (MD = 0.87 L/(min·m2), p < 0.0001); 6MWD: (MD = 43.41 m, p < 0.0001). In patients with moderate to severe POPH (n = 235), the following indicators improved significantly with PAH agents: mPAP (MD = −9.63 mmHg, p < 0.0001); PVR (MD = −259.78 dyn·s·cm−5, p < 0.0001); CO (MD = 1.76 L/min, p < 0.0001); Cardiac index: (MD = 1.01 L/(min·m2), p = 0.0027); 6MWD: (MD = 61.30 m, p < 0.0001).Conclusion: The application of PAH agents can improve cardiopulmonary hemodynamics and cardiac function in patients with POPH, especially in patients with moderate to severe POPH, and the above changes are more positive.Systematic Review Registration:https://inplasy.com, identifier INPLASY202250034.
- Top Cited PapersOpen Access
- 20 September 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (27) , 3002-3011
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
PURPOSE: Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study compared the efficacy and safety of donafenib versus sorafenib as first-line therapy for advanced HCC.PATIENTS AND METHODS: This open-label, randomized, parallel-controlled, multicenter phase II-III trial enrolled patients with unresectable or metastatic HCC, a Child-Pugh score ≤ 7, and no prior systemic therapy from 37 sites across China. Patients were randomly assigned (1:1) to receive oral donafenib (0.2 g) or sorafenib (0.4 g) twice daily until intolerable toxicity or disease progression. The primary end point was overall survival (OS), tested for noninferiority and superiority. Efficacy was primarily assessed in the full analysis set (FAS), and safety was assessed in all treated patients.RESULTS: Between March 21, 2016, and April 16, 2018, 668 patients (intention-to-treat) were randomly assigned to donafenib and sorafenib treatment arms; the FAS included 328 and 331 patients, respectively. Median OS was significantly longer with donafenib than sorafenib treatment (FAS; 12.1 v 10.3 months; hazard ratio, 0.831; 95% CI, 0.699 to 0.988; P = .0245); donafenib also exhibited superior OS outcomes versus sorafenib in the intention-to-treat population. The median progression-free survival was 3.7 v 3.6 months ( P = .0570). The objective response rate was 4.6% v 2.7% ( P = .2448), and the disease control rate was 30.8% v 28.7% (FAS; P = .5532). Drug-related grade ≥ 3 adverse events occurred in significantly fewer patients receiving donafenib than sorafenib (125 [38%] v 165 [50%]; P = .0018).CONCLUSION: Donafenib showed superiority over sorafenib in improving OS and has favorable safety and tolerability in Chinese patients with advanced HCC, showing promise as a potential first-line monotherapy for these patients.
- 20 September 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (27) , 3002-3011
Top Cited PapersOpen AccessDonafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
PURPOSE: Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study compared the efficacy and safety of donafenib versus sorafenib as first-line therapy for advanced HCC.PATIENTS AND METHODS: This open-label, randomized, parallel-controlled, multicenter phase II-III trial enrolled patients with unresectable or metastatic HCC, a Child-Pugh score ≤ 7, and no prior systemic therapy from 37 sites across China. Patients were randomly assigned (1:1) to receive oral donafenib (0.2 g) or sorafenib (0.4 g) twice daily until intolerable toxicity or disease progression. The primary end point was overall survival (OS), tested for noninferiority and superiority. Efficacy was primarily assessed in the full analysis set (FAS), and safety was assessed in all treated patients.RESULTS: Between March 21, 2016, and April 16, 2018, 668 patients (intention-to-treat) were randomly assigned to donafenib and sorafenib treatment arms; the FAS included 328 and 331 patients, respectively. Median OS was significantly longer with donafenib than sorafenib treatment (FAS; 12.1 v 10.3 months; hazard ratio, 0.831; 95% CI, 0.699 to 0.988; P = .0245); donafenib also exhibited superior OS outcomes versus sorafenib in the intention-to-treat population. The median progression-free survival was 3.7 v 3.6 months ( P = .0570). The objective response rate was 4.6% v 2.7% ( P = .2448), and the disease control rate was 30.8% v 28.7% (FAS; P = .5532). Drug-related grade ≥ 3 adverse events occurred in significantly fewer patients receiving donafenib than sorafenib (125 [38%] v 165 [50%]; P = .0018).CONCLUSION: Donafenib showed superiority over sorafenib in improving OS and has favorable safety and tolerability in Chinese patients with advanced HCC, showing promise as a potential first-line monotherapy for these patients.
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Prevalence and Associated Factors of Portopulmonary Hypertension in Patients with Portal Hypertension: A Case‐Control Study
Background and Aims. There are few studies on the prevalence and clinical characteristics of portopulmonary hypertension (POPH) in patients with portal hypertension. In addition, invasive right heart catheterization further limits the clinical diagnosis of POPH patients. Methods. From January 2018 to December 2019, 1004 patients with portal hypertension were treated in the Department of Hepatology, the First Hospital of Jilin University. Based on the inclusion and exclusion criteria, 188 patients with portal hypertension were finally included. We collected complete clinical data, laboratory examinations, and imaging examinations. Patients were divided into a POPH group and a non‐POPH group based on echocardiographic results. We calculated the prevalence of POPH in patients with portal hypertension. The differences in clinical characteristics of the two groups of patients were compared. Results. The prevalence of POPH in patients with portal hypertension was 2.8%. Among the 188 patients with portal hypertension with fingertip oxygen saturation < 95% at rest, 28 patients had POPH (12 males and 16 females), with an average age of 63 ± 8, and 160 patients did not have POPH (110 males, 50 women), with an average age of 59 ± 11. The proportion of women in the POPH group (P < 0.01) and patients without liver cancer (P = 0.044) was high. Compared to patients without POPH, patients with POPH had lower hemoglobin (related to the severity of anemia, P < 0.01), higher creatinine (P < 0.05), and lower partial pressure of oxygen and carbon dioxide (P < 0.05). Patients with POPH had a higher incidence of atrial enlargement, ventricular enlargement, mitral valve regurgitation, tricuspid regurgitation, pulmonary artery widening, pericardial effusion, and aortic regurgitation than those without POPH. The risk of POPH did not increase with the aggravation of the Child‐Pugh classification. Conclusion. The prevalence of POPH in patients with portal hypertension is 2.8%. The proportion of women and nonliver cancer in POPH patients was higher than that in non‐POPH patients. In addition, the POPH group had higher creatinine and lower hemoglobin, and echocardiography showed that POPH patients had more cardiac structural changes. In patients with portal hypertension, the risk in patients with POPH has nothing to do with the Child‐Pugh classification and MELD score.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessPrevalence and Associated Factors of Portopulmonary Hypertension in Patients with Portal Hypertension: A Case‐Control Study
Background and Aims. There are few studies on the prevalence and clinical characteristics of portopulmonary hypertension (POPH) in patients with portal hypertension. In addition, invasive right heart catheterization further limits the clinical diagnosis of POPH patients. Methods. From January 2018 to December 2019, 1004 patients with portal hypertension were treated in the Department of Hepatology, the First Hospital of Jilin University. Based on the inclusion and exclusion criteria, 188 patients with portal hypertension were finally included. We collected complete clinical data, laboratory examinations, and imaging examinations. Patients were divided into a POPH group and a non‐POPH group based on echocardiographic results. We calculated the prevalence of POPH in patients with portal hypertension. The differences in clinical characteristics of the two groups of patients were compared. Results. The prevalence of POPH in patients with portal hypertension was 2.8%. Among the 188 patients with portal hypertension with fingertip oxygen saturation < 95% at rest, 28 patients had POPH (12 males and 16 females), with an average age of 63 ± 8, and 160 patients did not have POPH (110 males, 50 women), with an average age of 59 ± 11. The proportion of women in the POPH group (P < 0.01) and patients without liver cancer (P = 0.044) was high. Compared to patients without POPH, patients with POPH had lower hemoglobin (related to the severity of anemia, P < 0.01), higher creatinine (P < 0.05), and lower partial pressure of oxygen and carbon dioxide (P < 0.05). Patients with POPH had a higher incidence of atrial enlargement, ventricular enlargement, mitral valve regurgitation, tricuspid regurgitation, pulmonary artery widening, pericardial effusion, and aortic regurgitation than those without POPH. The risk of POPH did not increase with the aggravation of the Child‐Pugh classification. Conclusion. The prevalence of POPH in patients with portal hypertension is 2.8%. The proportion of women and nonliver cancer in POPH patients was higher than that in non‐POPH patients. In addition, the POPH group had higher creatinine and lower hemoglobin, and echocardiography showed that POPH patients had more cardiac structural changes. In patients with portal hypertension, the risk in patients with POPH has nothing to do with the Child‐Pugh classification and MELD score.